Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 1/20 | 0.68 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.68 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.68 |
| ▸ | CALCR | P30988 | 1/20 | 0.68 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.68 |
| ▸ | NPY2R | P49146 | 11/20 | 0.62 |
| ▸ | INSR | P06213 | 1/20 | 0.62 |
| ▸ | TFPI | P10646 | 2/20 | 0.59 |
| ▸ | PRLHR | P49683 | 3/20 | 0.59 |
| ▸ | CALCA | P06881 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511605 | 0.98 | RAMP1 (0.71) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL31692974 | 0.87 | RAMP1 (0.82) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29419171 | 0.87 | CALCR (0.71) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Davalintide SCHEMBL29533482 | 0.87 | RAMP1 (0.77) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Amylin SCHEMBL29351499 | 0.85 | RAMP1 (0.75) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL30078470 | 0.84 | RAMP1 (0.91) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29854921 | 0.83 | CALCR (0.77) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29360080 | 0.83 | CALCA (0.73) | RAMP3CALCRNPY2RTFPICALCA | |
| SCHEMBL29459653 | 0.83 | CALCA (0.73) | RAMP3CALCRNPY2RTFPICALCA | |
| SCHEMBL374892 | 0.83 | RAMP1 (0.78) | RAMP1RAMP2RAMP3CALCRCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3062 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| US-12622968-B2 | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115299-A1 | CALSEQUESTRIN-BASED METAL ION REACTIVE PARTICLE AND USES THEREOF | TOOLBIO CO LTD (KR) | 2026-04-30 | — | — | US | claimed |
| EP-4705326-A1 | GENE THERAPY FOR TREATMENT OF PROTEIN MISFOLDING DISEASES | Research Institute at Nationwide Children's Hospital (US) | 2026-03-11 | — | — | EP | claimed |
| US-12564674-B2 | Drug delivery device with messaging label | AMGEN INC (US) | 2026-03-03 | — | — | US | claimed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260041663-A1 | PREVENTION OF ROSACEA INFLAMMATION | UNIV CALIFORNIA (US) | 2026-02-12 | — | — | US | claimed |
| US-20220098313-A1 | Use of LEPR Agonists for Pain | REGENERON PHARMACEUTICALS, INC. | 2022-03-31 | — | — | US | claimed |
| WO-2022060827-A2 | USE OF LEPR AGONISTS FOR PAIN | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | claimed |
| EP-3969054-A1 | OIL-SOLUBLE DRUG CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | Aegis Therapeutics, LLC (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220072042-A1 | METHODS FOR IMPROVED IMMUNOTHERAPY | LEVITE MIA (IL) | 2022-03-10 | — | — | US | claimed |
| US-11266718-B2 | Methods of treating inflammatory skin disorders | NEPSONE EHF (IS) | 2022-03-08 | — | — | US | claimed |
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | claimed |
| US-20220048986-A1 | PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2022-02-17 | — | — | US | claimed |
| EP-3950708-A1 | METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG | Korea Institute of Ceramic Engineering and Technology (KR) | 2022-02-09 | — | — | EP | claimed |
| US-20220031809-A1 | COMPOUNDS FOR USE IN INDUCING MYOCARDIAL PERFUSION RECOVERY | EPOQE PHARMA APS (DK) | 2022-02-03 | — | — | US | claimed |
| US-20220023389-A1 | VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER | UNIVERSITY OF COPENHAGEN (DK) | 2022-01-27 | — | — | US | claimed |